GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cosciens Biopharma Inc (TSX:CSCI) » Definitions » EBITDA Margin %

Cosciens Biopharma (TSX:CSCI) EBITDA Margin % : -217.37% (As of Mar. 2025)


View and export this data going back to 1992. Start your Free Trial

What is Cosciens Biopharma EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cosciens Biopharma's EBITDA for the three months ended in Mar. 2025 was C$-4.68 Mil. Cosciens Biopharma's Revenue for the three months ended in Mar. 2025 was C$2.15 Mil. Therefore, Cosciens Biopharma's EBITDA margin for the quarter that ended in Mar. 2025 was -217.37%.


Cosciens Biopharma EBITDA Margin % Historical Data

The historical data trend for Cosciens Biopharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosciens Biopharma EBITDA Margin % Chart

Cosciens Biopharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.61 31.00 42.13 -39.07 -140.70

Cosciens Biopharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -67.64 -64.06 -286.86 -157.55 -217.37

Competitive Comparison of Cosciens Biopharma's EBITDA Margin %

For the Biotechnology subindustry, Cosciens Biopharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cosciens Biopharma's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Cosciens Biopharma's EBITDA Margin % falls into.


;
;

Cosciens Biopharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Cosciens Biopharma's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-19.218/13.659
=-140.70 %

Cosciens Biopharma's EBITDA Margin % for the quarter that ended in Mar. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2025 )/Revenue (Q: Mar. 2025 )
=-4.68/2.153
=-217.37 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cosciens Biopharma  (TSX:CSCI) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Cosciens Biopharma EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Cosciens Biopharma's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cosciens Biopharma Business Description

Traded in Other Exchanges
Address
c/o Norton Rose Fulbright Canada LLP, 222 Bay Street, Suite 3000, P.O. Box 53, Toronto, ON, CAN, M5K 1E7
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology. The Company has two reportable and operating segments: Active ingredient and Biopharmaceutical.
Executives
Dennis Turpin Director
Gilles Gagnon Director

Cosciens Biopharma Headlines

From GuruFocus